BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Revlimid lenalidomide regulatory update

Celgene submitted an MAA to the European Medicines Agency (EMA) for Revlimid lenalidomide for maintenance treatment of newly diagnosed multiple myeloma (MM)...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >